Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Read also

Nightmare bacteria

«Nightmare bacteria» cases on the rise in the US: CDC

NRx Pharmaceuticals

NRx Pharmaceuticals Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

Akari Therapeutics

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Breakthrough Therapy Designation To Povetacicept

Vertex: FDA Grants Breakthrough Therapy Designation To Povetacicept